Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13043
UPID:
STK4_HUMAN
Alternative names:
Mammalian STE20-like protein kinase 1; STE20-like kinase MST1; Serine/threonine-protein kinase Krs-2
Alternative UPACC:
Q13043; B2RCR8; Q15802; Q4G156; Q5H982; Q6PD60; Q9BR32; Q9NTZ4
Background:
Serine/threonine-protein kinase 4 (STK4), also known as Mammalian STE20-like protein kinase 1 and STE20-like kinase MST1, plays a crucial role in the Hippo signaling pathway, organ size control, and tumor suppression. It is involved in apoptosis, phosphorylating key substrates such as FOXO3 and SIRT1, and inhibiting PKB/AKT1.
Therapeutic significance:
STK4's involvement in Immunodeficiency 110 with lymphoproliferation highlights its potential as a target for therapeutic intervention. Understanding the role of STK4 could open doors to potential therapeutic strategies for treating this immunodeficiency and preventing associated lymphoma.